CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will ...
CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will present late-breaking oral presentations on revaccination data for both mRNA-1010, i ...
A European panel has backed expanding the RSV vaccine from adults aged 60 years or older to all adults aged 18 years or older ...
The Hearty Soul on MSN
First man in the US to get COVID jab reveals 'side effects' 6 years later
Neal Browning pushed this story back into view with a short social media post. Newsweek said he marked the 6-year anniversary of Moderna's first human trial. He described his "side effects" with ...
Moderna’s first big success was its coronavirus vaccine -- that product brought in $18 billion in revenue at its peak. The biotech recently submitted a flu vaccine candidate to regulators. But Moderna ...
Moderna (NASDAQ: MRNA) is best known for its coronavirus vaccine, a product that generated more than $18 billion in revenue at its peak in 2022 and helped drive the stock higher during the early days ...
The smaller, more volatile of these two companies has higher potential for significant gains. However, that also comes with a healthy dose of risk. Choosing between these two stocks may come down to ...
Moderna CEO Stéphane Bancel’s total compensation remained remarkably stable last year at $19.9 million, even as the vaccines company navigated a “challenging regulatory and business environment.” ...
A patent dispute over technology key to messenger RNA Covid-19 vaccines is settling with Moderna agreeing to pay $950 million up front and potentially more than $1 billion later, a resolution that ...
About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine landscape—Moderna has resolved a long-running patent feud. Moderna will pay $950 million ...
Shares of Moderna on Wednesday surged to their highest in more than a year after the pharmaceutical company said it reached a deal to resolve a dispute related to its COVID vaccine. Moderna MRNA said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results